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Abstract
Background: Bedaquiline was recently introduced into World Health Organization (WHO)-recommended regimens
for treatment of drug resistant tuberculosis. There is limited data on the long-term safety of bedaquiline. Because
bedaquiline prolongs the QT interval, there are concerns regarding cardiovascular safety. The Western Cape
Province in South Africa has an established pharmacovigilance programme: a targeted spontaneous reporting
system which solicits reports of suspected adverse drug reactions (ADRs) in patients with HIV-1 and/or tuberculosis
infection. Since 2015, bedaquiline has been included in the treatment regimens recommended for resistant
tuberculosis in South Africa. We describe ADRs in patients on bedaquiline-containing tuberculosis treatment that
were reported to the Western Cape Pharmacovigilance programme.
Methods: We reviewed reports of suspected ADRs and deaths received between March 2015 and June 2016
involving patients receiving bedaquiline-containing tuberculosis treatment. A multidisciplinary panel assessed
causality, and categorised suspected ADRs using World Health Organisation-Uppsala Monitoring Centre system
categories. “Confirmed ADRs” included all ADRs categorised as definite, probable or possible. Preventability was
assessed using Schumock and Thornton criteria. Where a confirmed ADR occurred in a patient who died, the panel
categorised the extent to which the ADR contributed to the patient’s death as follows: major contributor,
contributor or non-contributor.
Results: Thirty-five suspected ADRs were reported in 32 patients, including 13 deaths. There were 30 confirmed
ADRs, of which 23 were classified as “possible” and seven as “probable”. Bedaquiline was implicated in 22 confirmed
ADRs in 22 patients. The most common confirmed ADR in patients receiving bedaquiline was QT prolongation
(8 cases, 7 of which were severe). A fatal arrhythmia was suspected in 4 sudden deaths. These 4 patients were all
taking bedaquiline together with other QT-prolonging drugs. There were 8 non-bedaquiline-associated ADRs, of
which 7 contributed to deaths.
Conclusions: Confirmed ADRs in patients receiving bedaquiline reflect the known safety profile of bedaquiline.
Quantifying the incidence and clinical consequences of severe QT-prolongation in patients receiving bedaquiline-
containing regimens is a research priority to inform recommendations for patient monitoring in treatment
programmes for drug resistant tuberculosis. Pharmacovigilance systems within tuberculosis treatment programmes
should be supported and encouraged, to provide ongoing monitoring of treatment-limiting drug toxicity.
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Background
South Africa has high tuberculosis (TB) incidence and a
growing epidemic of multidrug resistant (MDR) and
extensively drug resistant (XDR) TB [1]. Drug resistant
TB treatment regimens are prolonged, poorly tolerated,
and result in poor outcomes [2]. The oral diarylquino-
line, bedaquiline, was approved by the Food and Drug
Administration (FDA) for the treatment of MDR-TB in
2012, under the provisions of the accelerated approval
regulations for serious or life-threatening illnesses [3].
This approval was based on the results of two phase IIb
clinical trials in which patients with MDR- TB were ran-
domised to bedaquiline or placebo, in combination with
a five drug background regimen: bedaquiline signifi-
cantly reduced time to sputum culture conversion and
increased the proportion with culture conversion [4, 5].
In 2013, WHO recommended that bedaquiline be used
in treatment of MDR and XDR TB, but emphasized the
need for robust pharmacovigilance strategies in TB
treatment programmes to actively monitor safety of
bedaquiline [6].
Two potentially fatal adverse drug reactions (ADRs)
from bedaquiline are QT prolongation and liver injury.
Greater QT prolongation was seen in the bedaquiline
arm of the phase 2 trial (mean increase in QT 15.4 ms
with bedaquiline versus 3.3 ms with placebo). In the
trial there was also unexplained excess mortality in
bedaquiline-exposed participants [5]. Almost all of the
deaths in the bedaquiline arm occurred after the bedaqui-
line was stopped, but bedaquiline has a very long half-life
(5.5months) [7] and could therefore still be implicated in
these deaths.
Bedaquiline was officially introduced into the TB
treatment programme in South Africa in March 2015,
for use in selected patients with MDR (either drug
intolerance or both inhA and katG mutations) and in all
patients with pre-XDR and XDR-TB [8]. Western Cape
Department of Health treatment guidelines recom-
mended baseline and monthly ECG monitoring for the
duration of bedaquiline therapy [9]. The quinolone
moxifloxacin prolongs the QT interval more than levo-
floxacin [10] therefore the guideline recommended
switching from moxifloxacin to levofloxacin to minimize
additive QT prolongation. According to Western Cape
Department of Health treatment guidelines, a QTc inter-
val > 500msec or an increase > 50msec above baseline
without symptoms or the presence of Torsades de pointes
or other serious ventricular dysrhythmias was graded as
severe, with bedaquiline withdrawal advised [9].
When bedaquiline was introduced into the TB treat-
ment programme, health care workers in the Western
Cape Province of South Africa were actively encouraged
to report all suspected serious adverse drug reactions and
all deaths in patients receiving bedaquiline-containing TB
treatment to the Western Cape Pharmacovigilance
Programme (a targeted spontaneous reporting system for
suspected ADRs in patients with HIV and/or TB
infection). We describe these reports.
Methods
The Western Cape provincial HIV and TB program-
matic pharmacovigilance system, founded in 2005, is a
collaboration between the Western Cape Province Depart-
ment of Health and the Division of Clinical Pharmacology
at the University of Cape Town. The pharmacovigilance
programme solicits reports of suspected ADRs that are
life-threatening, result in hospitalisation/prolonged hospi-
talisation, result in permanent disability or incapacity, or
require cessation of drug, as well as reports of deaths and
birth defects, from all public health sector facilities in the
Western Cape Province. Reports are submitted on a
structured reporting form which requests the following
information (if applicable): patient age, sex, weight, preg-
nancy status, HIV status, CD4 count, co-morbidities,
medication history (including all concomitant medica-
tions), details of the adverse event, relevant laboratory
investigations and management of the adverse event,
including response to drug withdrawal if this occurs.
Reports are prospectively entered into a repository. A
pharmacist performing initial assessment of the report
contacts the reporter to request additional clinical infor-
mation for causality and preventability assessment, if
required.
During the first year after bedaquiline was introduced
into the TB treatment programme, reporting of sus-
pected ADRs was actively encouraged by the provincial
department of health, with repeated reminders to clini-
cians treating resistant TB. We describe suspected ADRs
and deaths in patients on bedaquiline reported to the
pharmacovigilance system from March 2015, when
bedaquiline was introduced into the programme, until
June 2016.
Causality assessment of suspected ADRs was per-
formed using the World Health Organisation-Uppsala
Monitoring Centre (WHO-UMC) system [11]. Causality
assessment was performed by a team comprising an in-
formation pharmacist, a clinical pharmacologist and a
physician, with input from other specialties, if required.
“Confirmed ADRs” included all suspected ADRS that we
categorised as definite, possible or probable according to
the WHO-UMC criteria [11]. A definite ADR required:
an event or laboratory abnormality with a plausible
temporal association with the drug, can’t be explained
by the disease or other drugs, plausible response to
withdrawal, a pharmacologically or phenomenologically
definitive event and a positive rechallenge (if indicated).
A probable ADR required: an event or laboratory abnor-
mality with a plausible temporal association with the
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drug, unlikely to be due to disease or other drugs,
response to withdrawal reasonable and rechallenge not a
prerequisite. A possible ADR required: an event or
laboratory abnormality with a plausible temporal associ-
ation with the drug, could be explained by disease or
other drugs and information on drug withdrawal is
lacking/unclear [11]. In the event of death, we further
categorised the ADR as a contributor, major contributor
or non-contributor to the patient’s death.
Preventability was assessed using Schumock and
Thornton criteria [12]; if any of these criteria were met
the ADR was categorised as preventable. Criteria are as
follows: drug prescribed inappropriate, dose/route/fre-
quency inappropriate, required laboratory monitoring
not performed, history of a previous reaction to the
drug, drug interaction, toxic serum drug level and poor
compliance.
Continuous variables were summarised as mean and
standard deviation (SD) if normally distributed, and me-
dian and interquartile range (IQR) if non-parametrically
distributed.
Results
We received reports of suspected adverse drug reactions
(ADRs) involving 32 patients on bedaquiline-containing
TB therapy between March 2015 and June 2016. These
included 13 reports of deaths. During this time, 549
patients were initiated on bedaquiline in the Western
Cape.
The reports came from urban healthcare facilities
managing resistant TB, and all but one were submitted
by doctors (31/32, 97%). Patient characteristics are de-
scribed in Table 1. Half of the reports involved patients
known to be infected with HIV, with a median CD4
count of 51 cells/μL (IQR 37 to 65). HIV status was
missing in seven cases (22%).
Thirty-five suspected ADRs were reported in the 32
patients. We confirmed 30 ADRs, of which we assessed
23 ADRs as “possible” and seven as “probable”. The 30
confirmed ADRs are described in Table 2. The most
commonly reported ADR was QTcF prolongation in 8
patients. Seven of these patients had severe QTcF
prolongation. Bedaquiline was implicated in 22 of the
confirmed ADRs (73%); in all of these ADRs there were
one or more concomitant drugs that were also implicated.
In eight of the confirmed ADRs (27%) the causality assess-
ment panel attributed causality to a drug/drugs other than
bedaquiline. Seven of these non-bedaquiline-associated
ADRs contributed to deaths.
In nine of the 13 deaths we identified one or more
ADRs that contributed to the death (Table 2). Three
deaths were assessed as “disease-related” and one was
“unassessable” due to the paucity of information pro-
vided by the reporter. There were four sudden deaths
due to suspected arrhythmia. In all of these cases,
patients were on bedaquiline in combination with other
drugs known to cause QT prolongation (see Table 2). In
addition, one of these patients had a history of hypokal-
aemia and hypomagnesaemia. The other ADRs impli-
cated in deaths were antibiotic-associated diarrhoea
(moxifloxacin implicated), pancytopenia (linezolid impli-
cated), and elevated INR with increased bleeding
(warfarin implicated). There was more than one ADR
implicated in two deaths. The first of these patients had
antibiotic-associated diarrhoea with confirmed C. difficile
on stool culture (levofloxacin implicated) and renal failure
(kanamycin implicated). The second patient had renal fail-
ure (kanamycin implicated) and a seizure (moxifloxacin
implicated).
We received five reports of pustular/acneiform rashes.
All of these patients were taking multiple concomitant
medications that could be implicated, making causality
attribution difficult. None of the rashes were treatment-
limiting or life threatening.
Two preventability issues were identified. One patient
remained on moxifloxacin after starting bedaquiline in-
stead of being switched to levofloxacin. Levofloxacin is
the preferred quinolone to use in combination with
bedaquiline as it has a lesser effect on QT prolongation.
A second patient had a raised INR whilst on warfarin
treatment and no adjustment in warfarin dose was
recorded on the report.
Discussion
The ADRs reported to the Western Cape pharmacovigi-
lance programme are consistent with the known safety
profile of bedaquiline and other drugs used in drug re-
sistant TB treatment. The most commonly reported
ADR in our case series was QTcF prolongation. In all
cases patients were receiving multiple QT-prolonging
agents: bedaquiline in combination with clofazamine
and/or either moxifloxacin or levofloxacin. The four
sudden deaths were all in patients receiving multiple
QT-prolonging drugs.
Rashes, in particular pustular/acneiform rashes, were
commonly reported. All patients were on multiple medi-
cines that could be implicated. None of the rashes were
severe.
Table 1 Patient characteristics (n = 32)
Characteristic
Median age (IQR) years 30 (21 to 37)
Male sex [n (%)] 12 (38%)
Known HIV- infected [n (%)] 16 (50%)
Mean number of concomitant medicines (SD) 7.4 (1.5)
Median days on bedaquiline (IQR) 38.5 (13.5 to 88)
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Table 2 Confirmed ADRs
Organ system ADR Number of reports Number of patients who died in
whom ADR occurred (number of
deaths in which ADR was implicated)
Implicated drugsa (number of
reports in which drug implicated)
Cardiovascular Sudden death -suspected arrhythmia 4 4 (4) Bedaquiline (4)
Clofazimine (4)
Levofloxacin (4)
QTcF prolongation 8 1 (0) Bedaquiline (8)
Clofazimine (7)
Levofloxacin (6)
Moxifloxacin (1)
Skin Acneiform rash 2 0 Bedaquiline (2)
Clofazimine (2)
Emtricitabine (1)
Ethionamide (1)
Isoniazid (1)
Levofloxacin (2)
Linezolid (2)
Lopinavir/ritonavir (1)
Para-aminosalicylic acid (2)
Pyrazinamide (2)
Tenofovir (1)
Terizidone (2)
Itchy rash 1 0 Bedaquiline (1)
Clofazimine (1)
Linezolid (1)
Para-aminosalicylic acid (1)
Pustular facial rash 3 0 Bedaquiline (3)
Clofazimine (3)
Ethionamide (1)
Isoniazid (1)
Lamivudine (1)
Levofloxacin (3)
Linezolid (3)
Nevirapine (1)
Para-aminosalicylic acid (3)
Pyrazinamide (3)
Tenofovir (1)
Terizidone (3)
Rash 1 0 Bedaquiline (1)
Clofazimine (1)
Isoniazid (1)
Levofloxacin (1)
Linezolid (1)
Para-aminosalicylic acid (1)
Pyrazinamide (1)
Terizidone (1)
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Previous studies have reported a similar pattern of
ADRs attributed to bedaquiline. In a phase 2 randomised
controlled trial of bedaquiline versus placebo (on a back-
ground of 5 additional anti-tuberculosis drugs) there was
an increased risk of QTcF prolongation with bedaquiline
[5]. There was also an unexplained increased risk of
death associated with bedaquiline in this study- 10 out
of 79 patients randomised to bedaquiline and 2 out of
81 randomised to placebo died [4, 5]. In an open-label,
single arm observational study 2 out of 233 patients re-
ceiving bedaquiline developed clinically significant QTcF
prolongation (> 500 msec)- both patients were also re-
ceiving clofazimine concomitantly [13]. These studies
prompted the inclusion of a black box FDA warning of
increased risk of sudden death and QTcF prolongation
in the prescribing information [7]. Prescribers were ad-
vised to prescribe bedaquiline only if alternative effective
treatment is not available, and cautioned about prescrib-
ing concomitant drugs known to have effects on the QT
interval, which may have additive effects [7]. However,
in practice there is a limited number of drugs known to
be effective against MDR-TB, and many of these affect
the QT interval (bedaquiline, clofazimine, moxifloxacin
and to a lesser extent, levofloxacin).
There is limited data on cardiovascular safety of long-
term bedaquiline exposure. A South African observa-
tional cohort reported minimal increase of QT after
bedaquiline initiation, but this study is flawed in that a
third of the patients were taking moxifloxacin, which is
known to prolong QT, at the time of baseline ECG [8].
In 24 patients in that cohort, QT increased by more
than 50ms after bedaquiline initiation, with QT > 500
ms in three patients [8]. QTcF> 500 ms occurred in 11%
of patients treated with bedaquiline in a French
observational cohort but no arrhythmias were reported
[14]. A systematic review of the available evidence on
the cardiac safety of bedaquiline reported QTc prolonga-
tion > 500 msec in 3.2% of patients [15].
QT prolongation was the most frequently reported
ADR in our case series. QT prolongation was reported
in 1.4% of patients initiated on bedaquiline-containing
TB treatment during the study period (8/549); severe
QTc prolongation was reported in 1.2% (7/549). The
four sudden deaths reported are concerning, as all were
in patients receiving three drugs known to prolong the
QT. Current treatment protocols recommend baseline
and monthly ECGs for patients receiving bedaquiline.
Access to ECG monitoring in resource limited settings is
limited. However, more data on long term cardiovascular
safety of bedaquiline-containing regimens, and incidence
of life-threatening arrhythmias is required to guide
future recommendations for baseline and on-treatment
ECG monitoring. This is of particular importance as
MDR and XDR treatment regimens frequently include
multiple QT- interval-prolonging drugs.
A recent large retrospective cohort study in South Africa
compared outcomes in patients with resistant TB treated
with bedaquiline containing regimens to those not receiving
bedaquiline and found that bedaquiline improved survival
in both MDR and XDR TB [16]. These data are reassuring,
especially in view of the black box warning about bedaqui-
line potentially increasing mortality. As use of bedaquiline
expands in TB treatment programmes, pragmatic guidance
regarding cardiovascular monitoring is needed.
This study has several limitations. Cases were reported
to a voluntary, targeted spontaneous reporting system.
There is likely to be under-reporting, and we cannot
calculate incidence. Causality assessment was
Table 2 Confirmed ADRs (Continued)
Organ system ADR Number of reports Number of patients who died in
whom ADR occurred (number of
deaths in which ADR was implicated)
Implicated drugsa (number of
reports in which drug implicated)
Gastrointestinal Antibiotic-associated diarrhoea 2 2 (2) Levofloxacin (1)
Moxifloxacin (1)
Musculoskeletal Arthralgia 3 0 Bedaquiline (3)
Levofloxacin (1)
Para-aminosalicylic acid (3)
Pyrazinamide (2)
Haematological Increased bleeding risk 1 1 (1) Warfarin (1)
Pancytopenia 1 1 (1) Linezolid (1)
Neurologic Psychosis 1 0 Levofloxacin (1)
Terizidone (1)
Seizure 1 1 (1) Moxifloxacin (1)
Renal Renal failure 2 2 (2) Kanamycin (2)
a Multiple drug suspects may be implicated in an ADR
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challenging as patients were often extremely ill and on
multiple medications. A strength of our approach is that
causality assessment was performed by a multidisciplin-
ary team.
Conclusion
MDR-TB and especially XDR-TB has a poor prognosis,
and bedaquiline-containing therapy may improve cure
rates and reduce mortality [8, 16]. However, the drugs
used in MDR treatment have significant associated tox-
icities. Pharmacovigilance systems should be supported
and encouraged within MDR-treatment programmes, to
provide ongoing monitoring for treatment-limiting tox-
icity. Robust data on incidence and prevalence of serious
ADRs in patients receiving bedaquiline containing TB
treatment, and QT prolongation in particular, is a re-
search priority to guide programmatic recommendations
for optimal monitoring of patients receiving bedaquiline.
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